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Abstract
Background: Diabetic retinopathy (DR) is the leading cause of blindness in type 1 Diabetes Mellitus (DM) patients,
as a consequence of impaired blood flow in the retina. Optical coherence tomography angiography (OCTA) is a
newly developed, non-invasive, retinal imaging technique that permits adequate delineation of the perifoveal vascular
network. It allows the detection of paramacular areas of capillary non perfusion and/or enlargement of the foveal
avascular zone (FAZ), representing an excellent tool for assessment of DR. The relationship of these microvascular
changes with systemic factors such as metabolic control or duration of the disease still needs to be elucidated.
Methods: Prospective, consecutive, large-scale OCTA study. A complete ocular examination including a comprehensive
series of OCTA images of different scan sizes captured with 2 OCT devices (Cirrus HD-OCT, Carl Zeiss Meditec, Dublin, CA,
USA, and Triton Deep Range Imaging OCT, Topcon Corp, Topcon, Japan) will be obtained as part of the yearly routine follow
up visits in type 1 DM patients seen in the Diabetes Unit of the Endocrinology department which give written informed
consent to participate in the project. The aim of this study is to investigate the relationship between OCTA-
derived parameters and systemic factors, as metabolic control (Hb1Ac, lipid profile, cholesterol, etc), and other
relevant clinical factors as demographics or duration of the disease.
Discussion: This study is directed to investigate the relationship between the status of the perifoveal vascular
network and systemic markers of the disease, and in particular to study whether these changes reflect those
occurring elsewhere in the body affected by diabetic microvascular disease, as the kidneys or the brain. If
these relationships were demonstrated, early detection of these microvascular changes by OCTA could lead to
modifications in the pharmacological management of type 1 diabetic patients, as a way to reduce the risk of
future complications in both the eye and other organs.
Trial registration: ClinicalTrials.gov, trial number NCT03422965.
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Background
Diabetic retinopathy (DR) is the most important cause
of blindness in type 1 DM patients [1, 2]. It has been
postulated that selective loss of pericytes and thickening
of the basement membrane in retinal capillaries occur as
a result of exposure to elevated blood glucose over an
extended period of time, damaging the retinal vessels
and affecting the retinal blood flow in a time-dependant
manner [3]. To evaluate the vascular flow in the retina
of diabetic patients, fluorescein angiography (FA) re-
quires an intravenous injection and has been relegated
by the advent of non-invasive retinal imaging techniques
[4–10] Optical coherence tomography (OCT) is a light-
based technique that provides pseudo-histologic images
of the retinal structure, which has become the main
diagnostic tool in the management of retinal diseases
[11]. Unfortunately, the information given by conven-
tional OCT images is merely structural, and no informa-
tion about blood flow or perfused areas can be obtained,
being difficult to detect early changes in the retinal vas-
cular network of diabetic patients.
Recently, a novel OCT-based technique called OCT
angiography (OCTA) has been developed [12]. This
OCTA technique is based in a newly developed software
that employs an image processing algorithm, which ana-
lyses the decorrelation of the signal received by the OCT
in a specific geographic location at two different time-
points. Similar to Doppler ultrasonography, the detection
of two consecutive signals in a retinal vessel allows the de-
tection of blood flow, and permits a two-dimensional re-
construction of the retinal vascular network. The main
advantage of this technique is that it does not need the
use of an intravenous dye, and therefore can be performed
in a day-by-day basis in all patients. In the field of diabetic
retinopathy, OCTA represents an interesting opportunity
to evaluate the status of the perifoveal vascular network at
different times of the disease, to identify early changes
such as capillary dilation, enlargement of foveal avascular
zone (FAZ), paramacular areas of capillary nonperfusion
and presence of microaneurisms in a non-invasive way
[13–18].
These preclinical alterations could be correlated with
systemic factors such as time of diabetes evolution and
metabolic control, and may also reflect those occurring
elsewhere in the body affected by diabetic microvascular
disease. Early detection of these changes could lead to
modifications in the pharmacological management of
patients to avoid microvascular complications in both
retinal level and in other organs, such as the renal
glomerulus.
The aim of this ongoing study is to evaluate the role of
OCTA as a non-invasive screening tool for detecting
early changes in the perifoveal vascular network in a
large series of type 1 DM patients. The objectives of this
project are to study the characteristics of the perifoveal
capillary network using OCTA in patients with type 1
DM and controls, patients with type 1 DM with and
without diabetic retinopathy, and patients with type 1
DM at different times of disease progression. Moreover,
it is also directed to evaluate associations between the
characteristics of the perifoveal capillary network with
demographic factors, metabolic control and other risk
factors in type 1 DM patients.
Methods
Study design
Cross sectional, exploratory study in a cohort of type I
DM patients seen in the Endocrinology service in a 36-
month period from May 2017, with prospective collec-
tion of OCTA images and relevant clinical data. This
study is registered in the Clinical Trials website (Clini-
calTrials.gov, trial number NCT03422965). The Stand-
ard Protocol Items Recommendations for Interventional
Trials (SPIRIT) 2013 checklist was addressed in the
present paper (Additional file 1).
Ethics
This study was approved by the Institutional Review
Board of Hospital Clinic of Barcelona (study protocol
version 0.2, 23/11/2016). Written informed consent will
be obtained for all participants.
Study population
Type I Diabetes Mellitus patients undergoing yearly fol-
low up visits as per routine clinical care at the Diabetes
Unit of the Endocrinology service of our center will be
asked to participate in the study (Fig. 1).
Sample size
Given that no normative databases are available for ves-
sel density in normal eyes the project was designed in an
exploratory basis. In our hospital, an estimate number of
2000 type I DM patients are seen in a yearly basis, which
will be offered to enter the study voluntarily. All patients
willing to participate during the study period will be in-
cluded. We anticipate an estimated opt-out rate of 50%,
with a final estimated sample size of 1000 patients.
Inclusion and exclusion criteria
Patients with concomitant ocular pathology other than
diabetic retinopathy detected in the ocular examination
(uveitis, glaucoma, etc.) will be excluded from the ana-
lysis. Patients with inability to perform retinal images
and ocular examinations (OCT, OCTA, fundus retino-
graphies, biometry, etc.) or give written informed con-
sent will not be included in the study.
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Study groups
Type I DM patients with and without existing diabetic
retinopathy (DR) will be included in the study. Both
groups will be classified by duration of diabetic disease
(defined as date of type I DM diagnosis), in 3 main
groups: A. ≤5 years from diagnosis, B. > 5 - < 15 years
from diagnosis, and C. ≥15 years from diagnosis. Sub-
group analysis will include also treatment type, glycemic
control (glycaemia and HbA1c), body mass index, lipid
profile and kidney function tests. A cohort of 100 nor-
mal eyes (controls) from a pool of healthy volunteers
with clear media and without retinal disease will
undergo retinal imaging with OCTA for comparison
with type 1 DM cases images.
Interventions
Systemic data
Systemic status of the diabetic disease will be evaluated
in routine clinical care examinations in the Diabetes
Unit of the Endocrinology service, and clinical data col-
lected will include: Demographics, date of diagnosis,
duration of disease, treatment type, glycaemia, HbA1c
levels, concomitant pathology (hypertension, etc.), body
mass index, lipid profile (total cholesterol, triglycerides,
HDL-cholesterol, LDL-cholesterol) and kidney function
tests (urinary albumin excretion, estimated filtration
glomerular rate).
Ocular data
Patients identified in the Endocrinology service will be
referred to the Ophthalmology service. In the eye clinics,
a complete eye examination will be performed. Clinical
data collected in this visit will include: Best-corrected
visual acuity, biomicroscopy, intraocular pressure, retinal
fundus exam and biometry (IOL Master, Carl Zeiss
Meditec, Dublin, CA). A comprehensive battery of OCT
and OCTA images will be performed, described below.
OCTA images scanning protocols
Two optical coherence tomography angiography devices
will be employed to obtain OCTA retinal images. Fur-
ther retinal imaging techniques including fundus retino-
graphy (Optomap, Optos, Inc) and structural OCT will
be performed.
Cirrus HD-OCT (Carl Zeiss Meditec, Dublin, CA, USA)
A 6 × 6 mm OCT macular cube centered in the fovea
will be captured, and measurements of retinal and chor-
oidal thicknesses in each subfield of the Early Treatment
Diabetic Retinopathy Study (ETDRS) grid will be
Fig. 1 Patient flow diagram. Type 1DM patients seen in the Endocrinology service for their yearly revision will be invited to participate in the
study (Researchers 6, 7 and 8). Those willing to participate will give informed consent and will be referred to the Ophthalmology service for a
complete eye examination (Researcher 5) which include capture of a comprehensive battery of OCT and OCTA image datasets (Researcher 9).
These images will be evaluated (Principal investigator and researchers 1–4) and processed with commercial and research softwares (Researcher
10) to obtain objective measurements of OCTA derived parameters (i.e. vessel density, etc.) which will be correlated to systemic markers (i.e.
glycated haemoglobin, etc.)
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obtained using the device’s manufacturer built-in soft-
ware. Using the Angioplex OCTA, images will be cap-
tured with the 3 × 3, 6 × 6 and 8 × 8 mm scanning
protocol (Fig. 2). This image will be subsequently loaded
in the image processing software.
Triton deep range imaging (DRI) OCT (Topcon Corp,
Topcon, Japan)
A 12 × 9 mm OCT macular cube centered in the fovea
will be captured, and measurements of retinal and chor-
oidal thicknesses in each subfield of the Early Treatment
Diabetic Retinopathy Study (ETDRS) grid will be ob-
tained using the device’s manufacturer built-in software.
Using the OCTA scanning protocol, a 6 × 6 mm image
of the scanned cube centered in the fovea will be ob-
tained. This image will be subsequently loaded in the
image processing software.
Controls: For validity of readings of the study device
and as an internal normative database, a cohort of 100
normal eyes (controls) from a pool of healthy volunteers
with clear media and without retinal disease will
undergo retinal imaging and OCTA-derived measure-
ments will be calculated. The mean intensity of the fo-
veal avascular zone (FAZ) of these eyes will be
determined to establish the reference for detection of
flow in the macula.
Data collection and data management
Systemic and ocular data will be obtained from the hos-
pital electronic medical records system and will be col-
lected in a pseudoanonymized database by the study
team for confidentiality reasons. The OCT and OCTA
images will be stored in the hospital servers and a back-
up copy will be exported to encrypted hard disk drives
that will remain physically in the hospital. All access to
this data will be restricted only to the study team, and a
formal data monitoring committee will not be consti-
tued. Data sharing agreements will be specifically ob-
tained from the sponsor of the study (Fundació Clínic
para la Recerca Biomedica, at Hospital Clínic of Barce-
lona) by the study team for image analysis collaborations
with third parties, as specifically indicated in the written
informed consent signed by study participants.
Main outcome measures
Main outcome measures to be determined will be A)
parafoveal and perifoveal vessel density, B) total avascu-
lar area, and C) foveal avascular zone.
Comparisons will be made between these measure-
ments in:
a) controls and type I DM eyes,
b) type I DM eyes with no DR and DR
c) type I DM eyes with no DR and different duration
of disease timeframes
d) type I DM eyes with DR and different duration of
disease timeframes
Secondary outcome measures include subgroup ana-
lysis of vessel density by treatment type, glycemic con-
trol (glycaemia and HbA1c), metabolic index, body mass
index, and kidney function tests.
Statistical methods
Descriptive and frequency statistics will be used to assess
qualitative variables. Normality of quantitative variables
(i.e. pixel area) will be examined using histograms and
the Kolmogorov-Smirnov test protected by the Bonfer-
roni correction. To assess differences in quantitative
measurements between study groups, parametric and
non-parametric tests will be performed as appropriate,
respectively. Correlation between clinical data and
OCTA derived measurements will be analyzed using a
multivariate regression model to assess the effects of
clinical characteristics on these values. Visual acuity
measured in Snellen notation was converted to logMAR
(logarithm of the minimum angle of resolution) equiva-
lents for the purposes of statistical analysis. VA values
Fig. 2 Examples of OCTA image datasets collected for each individual patient and eye included in the study (3 × 3, 6 × 6 and 8 × 8 mm scan
sizes, Angioplex, Cirrus HD-OCT, Carl Zeiss Meditec, Dublin, CA, USA). Similar images were obtained with a different swept source device for each
study eye (3 × 3, 6 × 6 and 9 × 9 mm, Triton Deep Range Imaging -DRI- OCT, Topcon Corp, Topcon, Japan)
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recorded as counting fingers (CF), hand movements
(HM), and perception of light (PL) were converted to
2.1, 2.4, and 2.7 LogMAR, respectively. A p value of less
than 0.05 will be considered statistically significant. All
statistical analysis will be performed using IBM SPSS
Statistics software version 21.0 (IBM Corp., Armonk,
NY, USA).
Discussion
This study is directed to evaluate the potential role of OCTA
as a useful tool to inform the status of the macular
microvascular network in type 1 Diabetes Mellitus patients.
Its prospective nature and collaborative design between en-
docrinologists and ophthalmologists may allow the recruit-
ment of a large cohort of type 1 DM patients and controls to
permit the study of potential relationships between the peri-
foveal vascular network parameters obtained with OCTA
and systemic markers of the disease. The positive or negative
results of this study will be communicated in scientific meet-
ings and publications. If these relationships are identified
OCTA may be included in the screening program of type 1
DM patients, as these changes may preceed the progression
to more advanced stages of diabetic retinopathy (i.e. from
non DR to mild DR stages), as well as reflect the status of
the microvasculature in other parts of the body only access-
ible by invasive procedures, such as kidney or heart biopsies.
The potential of this technology will be evaluated in this and
future trials.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12880-019-0391-8.
Additional file 1. Standard protocol items: recommendations for
interventional trials (SPIRIT) 2013 checklist for the current study.
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